N patients with chronic myeloid leukemia treated with first-line dasatinib. Blood. 2012a; 120:291?94. [PubMed: 22645182] Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L. Assessment of BCR-ABL1 transcript levels at three months is definitely the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012b; 30:232?38. [PubMed: 22067393] Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010; 363:2511?521. [PubMed: 21175313] Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. A randomized trial of dasatinib one hundred mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012; 120:3898?905. [PubMed: 22915637] Saglio G, Kim DW, Issaragrisil S, Le CP, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362:2251?2259. [PubMed: 20525993] Sawyers CL.(R)-(Tetrahydrofuran-3-yl)methanamine Chemscene Chronic myeloid leukemia. N Engl J Med. 1999; 340:1330?340. [PubMed: 10219069]NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptBr J Haematol. Author manuscript; available in PMC 2015 January 01.Deininger et al.PageNIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptBr J Haematol. Author manuscript; obtainable in PMC 2015 January 01.Figure 1.Molecular responses of CML-CP sufferers, by therapy arm and approximate time on study, during the very first 12 months on therapy. Adjustments of Bcr-Abl mRNA level, relative to Group-specific median baseline values, are shown on a common log (log10) scale for individuals randomized to IM800 (strong line) or IM400 (dashed line) therapy. Boxplots displaying the 25th and 75th percentiles are connected at the median values. Horizontal dashed lines indicate no transform, 3-log (MMR) and 4-log (MR4.0) reduction from baseline. Month three: days 43?26; month 6: days 127?10; month 9: 211?94; month 12: days 295?20 (if a patient’s molecular response was tested additional than when within a month’s range of days, only the outcome obtained closest to day 90, 180, 270 or 365, respectively, was integrated in this Figure).Fmoc-3VVD-OH web Deininger et al.PMID:23439434 PageNIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptBr J Haematol. Author manuscript; available in PMC 2015 January 01.Deininger et al.PageNIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptBr J Haematol. Author manuscript; available in PMC 2015 January 01.Figure 2.Kaplan-Meier estimates of remedy outcomes for individuals randomized to IM400 (1) or IM800 (2). Tickmarks indicate censored observations. Number of patients remaining at threat are shown beneath each plot. (A) General survival; (B) Progression-free survival; (C) Relapse-free survival of patients who accomplished total haematologic response.TableCharacteristics of 145 CML-CP patients by remedy armIM400 (N=72) Median 50 74.